Negotiations for the Medicare Part D prices of 10 prescription drugs—enabled by The Inflation Reduction Act—has just been completed.
The Centers for Medicare and Medicaid Services (CMS) reported a $6 billion reduction in spending associated with the new negotiated prices, evaluated at 2023 volumes of prescriptions.
Using publicly-available data, the authors estimate savings consistent with CMS reporting, and find that 51.4% of the estimated savings ($3.28 billion) is accounted for by 3 drugs.
